• DeepScribe

  Participated · Seed · May 2021

  DeepScribe provides an AI-powered platform that automatically transcribes clinician–patient conversations to help doctors keep more accurate notes. The product is used by more than 400 physicians. To expand its market and reach more doctors, the company turned to venture capital and raised $30 million. Index Ventures led the $30 million round, with Nina Achadjian serving as the Index contact. Co-founder and CEO Akilesh Bapu will discuss the company’s fundraising strategy and partnership with Index on a TechCrunch Live episode. The company plans to use the capital to reach even more physicians and expand its market reach. DeepScribe builds an ambient AI medical scribe that listens to doctor–patient interactions and automatically generates compliant clinical notes in the physician's EHR. Its AI model, developed at UC Berkeley’s AI Research Lab, combines classical rule‑based natural language processing with modern deep learning techniques to capture both sides of conversations and distill them into summaries. The system interfaces with major EHR platforms including AdvancedMD, AthenaHealth, Claimpower, Elation, DrChrono and PracticeFusion. The company was founded by Akilesh Bapu, Matthew Ko and Kairui Zeng and is based in San Francisco, CA. Financially, DeepScribe raised $5.2M in seed funding.

• Endotronix

  Participated · Series D · Oct 2019

  Endotronix develops the Cordella Pulmonary Artery Sensor and the Cordella Heart Failure System to enable remote, pressure-guided management of heart failure patients. The Cordella System is designed to help patients feel better and stay out of the hospital through streamlined care and remote medication titration, providing comprehensive at-home health status and tools to securely collect and share health-related data with providers. The Cordella Sensor integrates pulmonary artery (PA) pressure data into the system to deliver trend-based management and support reimbursement for care delivery activities. The company expanded its Series D financing to $70 million to support the PROACTIVE-HF IDE clinical trial and commercialization of the Cordella System. PROACTIVE-HF is an FDA-approved, prospective, multi-center, randomized, controlled, single-blind pivotal trial planned to enroll over 950 NYHA Class III heart failure patients at up to 60 U.S. sites to evaluate safety and efficacy and to generate data for U.S. market access and reimbursement. Endotronix is also running the open-label SIRONA II CE Mark trial, enrolling 60 patients at up to eight European centers to evaluate safety and efficacy for European market access. Endotronix develops the Cordella Heart Failure System, a remote patient management platform that pairs cloud-based disease management software with an implantable wireless pulmonary artery sensor. The company’s platform collects and transmits daily patient data and hemodynamic insights to clinicians to enable guideline-based therapy and earlier detection of worsening heart failure. Endotronix intends to use the financing to commercialize the Cordella System and to advance clinical development and regulatory approval of the Cordella Pulmonary Artery Sensor through CE Marking and FDA Premarket Approval (PMA). The company is led by CEO Harry Rowland and will expand its board to include Fouad Azzam, Ph.D. The product offering includes outpatient hemodynamic management and aims to extend clinical care into the home. Endotronix is developing the Cordella™ Heart Failure System, an integrated platform that combines a cloud-based disease-management data system with outpatient hemodynamic management and an implantable wireless pulmonary artery sensor for early detection of worsening heart failure. The company focuses on providing comprehensive, reimbursable health management tools for patients with advanced heart failure. Led by CEO Harry Rowland, Endotronix is advancing Cordella through clinical development. Financially, the company received a $12m term loan from Silicon Valley Bank to support the Cordella clinical program. In July 2016 Endotronix completed a $32m Series C that included BioVentures Investors, SV Life Sciences (SVLS), Lumira Capital, Aperture Venture Partners, OSF Ventures, existing investors and a corporate strategic investor. The company is based in Woodridge, Illinois. Endotronix develops digital health medtech solutions that combine a cloud-based patient management system with an implantable wireless pulmonary artery sensor for outpatient hemodynamic management. Led by CEO Harry Rowland, the company's wireless solution integrates daily monitoring of key physiological data with improved communication between patients, caregivers and clinicians to enable earlier detection of worsening heart failure. The technology is intended to reduce heart failure hospitalizations through remote hemodynamic monitoring and care coordination. The company closed a $32m Series C financing to advance its clinical program and commercialization efforts. Endotronix intends to use the funds to conduct its clinical program, commercialize the cloud-based outpatient management system, and complete a safety and feasibility study for its implantable pulmonary artery sensor. The company is based in Woodridge, Illinois. Endotronix is developing wireless, implantable sensor technology licensed from NASA Glenn Research Center that transmits physiological data to a hand-held or wearable device and then to a remote data center. Its implants interact with an external hand-held measurement instrument to enable remote blood-pressure monitoring for congestive heart failure (CHF) patients. The company says the device could help patients and clinicians better monitor and treat heart failure and reduce hospitalizations. Endotronix was formed in early 2007 by Dr. Anthony Nunez and engineer Harry Rowland and began in Peoria before adding a Cleveland office with help from economic development partners. The firm has received a mix of small investments and grants, including a grant from the Lorain County Community College Foundation Innovation Fund. Recent financings include a $250,000 investment from JumpStart Ventures and an angels filing reporting $240,000 raised toward a $375,000 target.

• Fast Radius

  Participated · Series B · Apr 2019

  Fast Radius provides end-to-end additive manufacturing solutions via a platform that supports application discovery, product design and testing, engineering and economic evaluations, and production-grade manufacturing at scale. The company’s offerings include application discovery, accelerated new product development, and global fulfillment from Fast Radius factories using the latest additive technologies. Leadership is led by CEO Lou Rassey and COO Pat McCusker. Fast Radius has offices in Atlanta and Singapore and operates a production hub on-site at the UPS Worldport facility in Louisville, KY. The company plans to use new funding to scale its global manufacturing footprint and to expand its software development, application engineering, and sales teams. The platform is positioned to help customers identify potential applications and manufacture industrial-grade parts at scale.

No current team members are available.